Quick Answer
Solid Biosciences Inc. reported Cash and Equivalents of $59.90 million for fiscal year 2025.
Solid Biosciences Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $59.90M | -25.3% |
| 2024 | $80.23M | +8.4% |
| 2023 | $74.02M | -52.4% |
| 2022 | $155.38M | +30.4% |
| 2021 | $119.14M | -23.0% |
| 2020 | $154.74M | +103.5% |
| 2019 | $76.04M | -12.0% |
| 2018 | $86.37M | +65.8% |
| 2017 | $52.08M | +578.3% |
| 2016 | $7.68M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $61.36M | -4.7% | -55.8% |
| June 30, 2025 | $138.93M | +44.9% | -34.0% |
| March 31, 2025 | $210.63M | +79.1% | +162.5% |
| December 31, 2024 | $80.23M | +8.4% | +24.6% |
| September 30, 2024 | $64.39M | +31.3% | -32.8% |
| June 30, 2024 | $95.85M | +4.7% | -18.5% |
| March 31, 2024 | $117.57M | -28.6% | +58.9% |
| December 31, 2023 | $74.02M | -52.4% | +50.9% |
- Solid Biosciences Inc. showed a decrease of -25.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Solid Biosciences Inc.’s cash and equivalents has grown by 680.2% (from $7.68 million to $59.90 million).
- The most recent figure is from Solid Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: